306 related articles for article (PubMed ID: 35052876)
21. Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?
Guerreiro GTS; Longo L; Fonseca MA; de Souza VEG; Álvares-da-Silva MR
Hepatol Int; 2021 Apr; 15(2):380-391. PubMed ID: 33694066
[TBL] [Abstract][Full Text] [Related]
22. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
[TBL] [Abstract][Full Text] [Related]
23. From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-New Terminology in Pediatric Patients as a Step in Good Scientific Direction?
Flisiak-Jackiewicz M; Bobrus-Chociej A; Wasilewska N; Lebensztejn DM
J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33804296
[TBL] [Abstract][Full Text] [Related]
24. Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight.
Vasques-Monteiro IML; Souza-Mello V
World J Gastroenterol; 2021 Apr; 27(16):1738-1750. PubMed ID: 33967554
[TBL] [Abstract][Full Text] [Related]
25. Early-Life Exposure to Famine and Risk of Metabolic Associated Fatty Liver Disease in Chinese Adults.
Liu J; Wang G; Wu Y; Guan Y; Luo Z; Zhao G; Jiang Y
Nutrients; 2021 Nov; 13(11):. PubMed ID: 34836318
[TBL] [Abstract][Full Text] [Related]
26. Appendicular Skeletal Muscle Index and HbA1c Evaluate Liver Steatosis in Patients With Metabolic Associated Fatty Liver Disease.
Jin R; Wang X; Li X; Yang J; Liu B; Wei L; Liu F; Rao H
Front Med (Lausanne); 2022; 9():919502. PubMed ID: 35872790
[TBL] [Abstract][Full Text] [Related]
27. An Update in Epigenetics in Metabolic-Associated Fatty Liver Disease.
Rodríguez-Sanabria JS; Escutia-Gutiérrez R; Rosas-Campos R; Armendáriz-Borunda JS; Sandoval-Rodríguez A
Front Med (Lausanne); 2021; 8():770504. PubMed ID: 35087844
[TBL] [Abstract][Full Text] [Related]
28. Vitamin D and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD): An Update.
Barchetta I; Cimini FA; Cavallo MG
Nutrients; 2020 Oct; 12(11):. PubMed ID: 33126575
[TBL] [Abstract][Full Text] [Related]
29. Clinical Progression of Metabolic-Associated Fatty Liver Disease Is Rare in a Danish Tertiary Liver Center.
Laursen TL; Kjær MB; Kristensen L; Grønbæk H
J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566397
[TBL] [Abstract][Full Text] [Related]
30. G protein-coupled receptors: Key molecules in metabolic associated fatty liver disease development.
López-Méndez I; Méndez-Maldonado K; Manzo-Francisco LA; Juárez-Hernández E; Uribe M; Barbero-Becerra VJ
Nutr Res; 2021 Mar; 87():70-79. PubMed ID: 33601216
[TBL] [Abstract][Full Text] [Related]
31. A Shortcut from Metabolic-Associated Fatty Liver Disease (MAFLD) to Hepatocellular Carcinoma (HCC): c-MYC a Promising Target for Preventative Strategies and Individualized Therapy.
Guo F; Estévez-Vázquez O; Benedé-Ubieto R; Maya-Miles D; Zheng K; Gallego-Durán R; Rojas Á; Ampuero J; Romero-Gómez M; Philip K; Egbuniwe IU; Chen C; Simon J; Delgado TC; Martínez-Chantar ML; Sun J; Reissing J; Bruns T; Lamas-Paz A; Moral MGD; Woitok MM; Vaquero J; Regueiro JR; Liedtke C; Trautwein C; Bañares R; Cubero FJ; Nevzorova YA
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008356
[TBL] [Abstract][Full Text] [Related]
32. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
Chen S; Guo H; Xie M; Zhou C; Zheng M
Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).
Prasoppokakorn T; Pitisuttithum P; Treeprasertsuk S
J Clin Transl Hepatol; 2021 Dec; 9(6):939-946. PubMed ID: 34966657
[TBL] [Abstract][Full Text] [Related]
34. Pathophysiological mechanisms underlying MAFLD.
Kuchay MS; Choudhary NS; Mishra SK
Diabetes Metab Syndr; 2020; 14(6):1875-1887. PubMed ID: 32998095
[TBL] [Abstract][Full Text] [Related]
35.
Santos-Sánchez G; Cruz-Chamorro I; Álvarez-Ríos AI; Fernández-Santos JM; Vázquez-Román MV; Rodríguez-Ortiz B; Álvarez-Sánchez N; Álvarez-López AI; Millán-Linares MDC; Millán F; Pedroche J; Fernández-Pachón MS; Lardone PJ; Guerrero JM; Bejarano I; Carrillo-Vico A
Antioxidants (Basel); 2021 Jul; 10(8):. PubMed ID: 34439470
[TBL] [Abstract][Full Text] [Related]
36. Characterization of Gut Microbiome in Korean Patients with Metabolic Associated Fatty Liver Disease.
Oh JH; Lee JH; Cho MS; Kim H; Chun J; Lee JH; Yoon Y; Kang W
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801023
[TBL] [Abstract][Full Text] [Related]
37. MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.
Pan Z; Khatry MA; Yu ML; Choudhury A; Sebastiani G; Alqahtani SA; Eslam M
Ther Adv Endocrinol Metab; 2024; 15():20420188241252543. PubMed ID: 38808010
[TBL] [Abstract][Full Text] [Related]
38. Metabolic-associated fatty liver disease (MAFLD) in coeliac disease.
Rispo A; Imperatore N; Guarino M; Tortora R; Alisi A; Cossiga V; Testa A; Ricciolino S; Fiorentino A; Morisco F
Liver Int; 2021 Apr; 41(4):788-798. PubMed ID: 33319459
[TBL] [Abstract][Full Text] [Related]
39. Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease.
Huang SC; Su HJ; Kao JH; Tseng TC; Yang HC; Su TH; Chen PJ; Liu CJ
Gut Liver; 2021 May; 15(3):451-458. PubMed ID: 33431715
[TBL] [Abstract][Full Text] [Related]
40. Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD).
Méndez-Sánchez N; Díaz-Orozco LE
Med Sci Monit; 2021 Jul; 27():e933860. PubMed ID: 34248137
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
